

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

NOVARTIS PHARMACEUTICALS CORPORATION,  
Petitioner

v.

PLEXXIKON INC.,  
Patent Owner

---

Case No.: IPR2018-01287  
U.S. PATENT NO. 9,469,640

---

**PETITIONER'S MOTION FOR ADMISSION *PRO HAC VICE* OF  
THOMAS P. STEINDLER**

Mail Stop PATENT BOARD  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
*Submitted Electronically via the Patent Review Processing System*

Pursuant to 37 C.F.R. §42.10(c), Petitioner Novartis Pharmaceuticals Corporation (“NPC”) hereby moves for the *pro hac vice* admission of its counsel, Thomas P. Steindler.

The facts, supported by the attached Declaration of Thomas P. Steindler in Support of Motion for Admission *Pro Hac Vice* (“Steindler Dec.”), establish good cause to admit Mr. Steindler *pro hac vice* in this proceeding.

1. Lead counsel, Robert H. Underwood, is a registered practitioner.
2. Backup counsel, Thomas P. Steindler, is an experienced patent litigator who was first admitted to the bar in 1985. Steindler Dec. at ¶ 1. Mr. Steindler has acted as lead counsel in numerous patent cases, principally involving pharmaceutical patents, for the past 20 years. *Id.* at ¶ 2. Mr. Steindler is a member in good standing of the Bar of the District of Columbia and is admitted to practice in District of Columbia Court of Appeals, U.S. Court of Appeals 4th Circuit, U.S. Court of Appeals 9th Circuit, U.S. District Court District of Columbia, U.S. Court of Appeals 8th Circuit, U.S. Court of Appeals DC Circuit, U.S. Court of Appeals 7th Circuit, U.S. Court of Appeals 6th Circuit, U.S. Court of Appeals 11th Circuit, U.S. Court of Federal Claims, U.S. Court of Appeals for Federal Circuit, Supreme Court of the United States, U.S. Court of Appeals 1st Circuit, and U.S. District Court for the Eastern District of Texas. *Id.* at ¶ 3. Mr. Steindler has also been

admitted *pro hac vice* in the U.S. District Courts for the Districts of New Jersey and Delaware, as well as the Northern District of California. *Id.* Mr. Steindler has no suspensions or disbarments from practice, nor had any application for admission to practice denied, nor any sanctions or contempt citations imposed by any court or administrative body. *Id.* at ¶ 4.

3. Mr. Steindler has read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R. *Id.* at ¶ 5. Mr. Steindler will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a). *Id.* at ¶ 6.

4. Mr. Steindler has not applied to appear *pro hac vice* in any proceeding before the Office in the last three (3) years. *Id.* at ¶ 7.

5. Mr. Steindler has great familiarity with the subject matter at issue in this proceeding. *Id.* at ¶ 8. In particular, Mr. Steindler is lead counsel for NPC in the related district court proceeding involving the same U.S. Patent No. 9,469,640 which is the subject of the instant petition. *Plexxikon Inc. v. Novartis Pharmaceuticals Corp.*, Case No. 4:17-cv-04405-HSG (N.D. Cal) (filed Aug. 3, 2017). *Id.* Mr. Steindler was intimately involved in preparing, *inter alia*, NPC's invalidity contentions, which largely overlap with the grounds of invalidity asserted in the instant Petition. *Id.*

Respectfully submitted,

Dated: June 18, 2018

/Robert H. Underwood, Reg. No. 45,170/

---

Robert H. Underwood  
Reg. No. 45,170  
**MCDERMOTT WILL & EMERY LLP**  
28 State Street  
Boston, MA 02109  
Telephone: (617) 535-4093  
Fax: (617) 535-3800  
Email: runderwood@mwe.com

**Lead Counsel for Petitioner Novartis  
Pharmaceuticals Corporation**

**CERTIFICATE OF SERVICE**

Pursuant to C.F.R. §§ 42.6(e), I certify that, on June 18, 2018, I caused to be served true and correct copies of the foregoing “PETITIONER’S MOTION FOR ADMISSION *PRO HAC VICE* OF THOMAS P. STEINDLER” by Electronic Service (email and FTP) at the correspondence address of record for U.S. Patent No. 9,469,640 and additionally at other addresses known as likely to effect service, as follows:

<b>Firm</b> General Address	<b>Name(s)</b>	<b>Email Address(es)</b>
<b>SHEPPARD MULLIN RICHTER &amp; HAMPTON LLP</b> 379 Lytton Avenue Palo Alto, CA 94301	Lorna Tanner Wenrong Huang Lacie Hirayama Joy Nemirow Alex Nie Neeta Thakur Daniel Yannuzzi	LTanner@sheppardmullin.com WHuang@sheppardmullin.com LHirayama@sheppardmullin.com JNemirow@sheppardmullin.com ANie@sheppardmullin.com NThakur@sheppardmullin.com DYannuzzi@sheppardmullin.com
<b>DURIE TANGRI LLP</b> 217 Leidesdorff Street San Francisco, CA 94111	Daralyn J. Durie Laura E. Miller Raghav Krishnapriyan	SERVICE- BRAFF@durietangri.com
<b>YOUNG BASILE HANLON &amp; MACFARLANE, P.C.</b> 3001 W. Big Beaver Road Suite 624 Troy, MI 48084	Andrew R. Basile Eddie D. Woodworth Jeffrey D. Wilson Ryan T. McCleary	Plexxikon@youngbasile.com

/Robert H. Underwood, Reg. No. 45,170/

\_\_\_\_\_  
Robert H. Underwood